rimiducid
Showing 1 - 20 of 20
Hematologic Malignancy Trial in Pavia, Rome, Turin (BPX-501 T cells, rimiducid)
Active, not recruiting
- Hematologic Malignancy
- BPX-501 T cells
- rimiducid
-
Pavia, Italy
- +2 more
Jul 10, 2022
Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)
Not yet recruiting
- Solid Tumors
- Rimiducid
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2023
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 21, 2022
Lymphoma, Lymphoma, B-Cell, Immune System Diseases Trial in Chapel Hill (iC9-CAR19 T cells, Bendamustine, Fludarabine)
Recruiting
- Lymphoma
- +4 more
- iC9-CAR19 T cells
- +4 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- P-CD19CD20-ALLO1
- Rimiducid
-
La Jolla, California
- +7 more
Aug 25, 2023
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer Trial in San Francisco, Denver, San Antonio (P-MUC1C-ALLO1 CAR-T
Recruiting
- Breast Cancer
- +8 more
- P-MUC1C-ALLO1 CAR-T cells
- Rimiducid
-
San Francisco, California
- +4 more
Oct 26, 2022
Myeloma-Multiple, Myeloma, Plasma-Cell Trial run by the NCI (Cyclophosphamide, Fludarabine, Rimiducid)
Completed
- Myeloma-Multiple
- Myeloma, Plasma-Cell
- Cyclophosphamide
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 19, 2021
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
No longer available
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2021
Multiple Myeloma Trial in United States (P-BCMA-101 CAR-T cells, Rimiducid)
Terminated
- Multiple Myeloma
- P-BCMA-101 CAR-T cells
- Rimiducid
-
Gilbert, Arizona
- +15 more
May 17, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma Trial in United States (biological, drug, procedure)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +3 more
- BPX-501 dose 1
- +5 more
-
Atlanta, Georgia
- +7 more
Jul 10, 2022
Hurler Syndrome, Inherited Metabolic Disorder, Lysosomal Storage Disorder Trial in Los Angeles, Palo Alto (rivogenlecleucel,
No longer available
- Hurler Syndrome
- +4 more
- rivogenlecleucel
- rimiducid
-
Los Angeles, California
- +1 more
Oct 1, 2020
Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T
Active, not recruiting
- Prostatic Neoplasms, Castration-Resistant
- +16 more
- P-PSMA-101 CAR-T cells
- Rimiducid
-
Duarte, California
- +9 more
Nov 15, 2022
Leukemia, MDS, Lymphomas Trial (rivogenlecleucel, Rimiducid)
Withdrawn
- Leukemia
- +4 more
- rivogenlecleucel
- Rimiducid
- (no location specified)
Oct 1, 2020
Hematologic Malignancies Trial in Houston (BPX-501, AP1903)
Withdrawn
- Hematologic Malignancies
- BPX-501
- AP1903
-
Houston, TexasMD Anderson Cancer Center
Oct 1, 2020
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen
Recruiting
- HER-2 Gene Amplification
- +4 more
- chimeric antigen receptor (CAR) T cell therapy
-
Duarte, California
- +6 more
Aug 10, 2022
Acute Myeloid Leukemia, MDS Trial in Nashville, San Antonio (biological, drug, procedure)
Terminated
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- rivogenlecleucel
- +3 more
-
Nashville, Tennessee
- +1 more
Nov 11, 2020
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma Trial in Denver, Portland, Nashville (BPX-701, Rimiducid)
Unknown status
- Acute Myeloid Leukemia
- +2 more
- BPX-701
- Rimiducid
-
Denver, Colorado
- +2 more
Apr 23, 2020
Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Tumor, Myelodysplastic/Myeloproliferative Tumor, Unclassifiable
Withdrawn
- Acute Bilineal Leukemia
- +11 more
- Rivogenlecleucel
- Rimiducid
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 12, 2020
Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,
Recruiting
- Recurrent Neuroblastoma
- +3 more
- Cyclophosphamide
- +2 more
-
Palo Alto, California
- +3 more
Jan 25, 2023
Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)
Recruiting
- Neuroblastoma
- Osteosarcoma
- iC9.GD2.CAR.IL-15 T-cells
- +2 more
-
Atlanta, Georgia
- +1 more
Jan 4, 2023